Bristol-myers Squibb
Clinical trials sponsored by Bristol-myers Squibb, explained in plain language.
A global biopharmaceutical company developing medicines for cancer and other serious diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug shows promise for lung scarring in Long-Term safety trial
Disease control Not yet recruitingThis study looks at the long-term safety of a drug called admilparant in people with pulmonary fibrosis (lung scarring). About 2,277 adults who finished earlier studies will take the drug and be monitored for side effects. The goal is to see if the drug is safe to use over time, …
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for advanced melanoma: immunotherapy combo tested in india
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs, nivolumab and relatlimab, in people with advanced melanoma that hasn't been treated before. The goal is to see if the combination is safe and helps shrink tumors. About 30 adults and teens (ages 12 and up) in India will t…
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
A new hope for MDS patients: could this drug cut blood transfusions?
Disease control Not yet recruitingThis study looks at whether luspatercept, a drug given as first-line treatment, can help adults with low-risk myelodysplastic neoplasms (MDS) who need regular red blood cell transfusions. Researchers will follow about 190 participants for up to 2 years to see how often they achie…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for tough arthritis cases?
Disease control Not yet recruitingThis early-stage study tests a new drug, BMS-986528, in 84 adults with rheumatoid arthritis that hasn't responded well to other treatments. The main goal is to check safety and how the body processes the drug. Researchers will also look for signs that it might help control the di…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug duo aims to outsmart EGFR-mutant lung cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding an experimental drug called izalontamab brengitecan to the standard targeted therapy osimertinib works better than osimertinib alone or with chemotherapy for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Hope for families: new drug trial targets autism irritability in kids
Symptom relief Not yet recruitingThis study tests whether a new medication, KarXT + KarX-EC, can reduce irritability in children and teens (ages 5 to 17) with autism. About 176 participants will receive either the drug or a placebo. The main goal is to see if the drug improves irritability scores after 8 weeks.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Could a new pill tame Autism-Related irritability in kids?
Symptom relief Not yet recruitingThis Phase 3 study tests whether a combination of two drugs, KarXT and KarX-EC, can safely reduce irritability in children and adolescents aged 5 to 17 with autism spectrum disorder. About 176 participants will receive either the drug combo or a placebo for 8 weeks. The main goal…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Can a new drug work safely in patients with kidney failure?
Knowledge-focused Not yet recruitingThis study looks at how the experimental drug golcadomide is processed by the body in people with severe kidney impairment or end-stage renal disease compared to those with normal kidney function. The goal is to understand how kidney function affects drug levels and safety after …
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
What makes someone stop a lung fibrosis drug? a study asks patients directly
Knowledge-focused Not yet recruitingThis study uses web-based interviews to explore how adults in Japan with pulmonary fibrosis decide whether to continue or stop antifibrotic therapy after experiencing side effects. Researchers aim to understand the personal and psychological factors behind these decisions. The fi…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Korean patients with rare lung tumors monitored for drug safety in new study
Knowledge-focused Not yet recruitingThis study watches how well the drug repotrectinib works and what side effects it causes in Korean patients with a specific type of lung cancer or solid tumors that have certain gene changes. About 10 patients will be followed for up to 12 months during their normal treatment. Th…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New registry to map MDS in asia: no treatment, just data
Knowledge-focused Not yet recruitingThis study is a registry that will collect information from about 500 adults in Asia who have been diagnosed with myelodysplastic syndromes (MDS). Researchers will look at patient details like age, sex, medical history, lab results, and treatments received. The goal is to better …
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC